Testing Whether Dietary Salt Changes Eczema Severity in Adults
Compares salt tablets with placebo while adults follow a low-salt diet.
Plain-language title generated from the registry record
Registry title: The Impact of Dietary Salt on the Severity of Eczema
Key facts
- Where
- San Francisco, United StatesSee the 2 sites
- Phase
- Phase 4
Where in United States
- San Francisco VA Medical CenterSan Francisco, United StatesTaking people
- UCSF Mt Zion CampusSan Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT07447063
- Record updated
- 10 September 2026
- Original description
The goal of this clinical trial is to evaluate the feasibility of low-sodium diet to improve eczema severity. The main questions it aims to answer are:Read full original descriptionShow less
The Impact of Dietary Salt on the Severity of Eczema
The goal of this clinical trial is to evaluate the feasibility of low-sodium diet to improve eczema severity. The main questions it aims to answer are:
* Does a low-sodium diet improve eczema severity? * How does a low-sodium diet impact skin sodium concentration? * Is skin sodium concentration associated with eczema severity?
Researchers will ask all participant to follow a low-sodium diet, then compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake.
Participants will:
* Follow a low-salt diet for the duration of the 24-week study * Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa * Complete up to 4 virtual check-in visits * Visit the clinic 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI
Inclusion: Participants ages 18 years; Willing and able to undergo non-contrast MRI.
Exclusion: Antibiotic or immunomodulatory medications within the last month; Contraindications to MRI (such as cardiac pacemakers, claustrophobia, non-compatible intracranial vascular clips, IUDs, or other implants); A cardiac event in the past 6 months; Medications that influence sodium excretion (e.g., diuretics or SGLT2 inhibitors); Contraindications to sodium tablets; (Topical medications used exclusively on the head/neck or hands/feet (e.g., antifungal nail treatment, antidandruff shampoo, acne cleansers) are acceptable. Topical and systemic eczema treatments are acceptable if the participant has been on a stable dose for at least 2 months and still meets the severity entry criteria. Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the disease severity inclusion criteria.); Impaired function of the liver or kidney (glomerular filtration rate <60 mL/min).